Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q1 FY23 results · Apr–Jun 2022
Natco Pharma reported revenue from operations of ₹884.60 crore (up 115.6% from Q1 FY22) and net profit of ₹320.40 crore (up 327.2% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 884.60 | 410.30 | +115.6% | 596.80 | +48.2% |
| Other income | 34.30 | 17.00 | +101.8% | 13.80 | +148.6% |
| Total income | 918.90 | 427.30 | +115.0% | 610.60 | +50.5% |
| Profit before tax | 385.80 | 91.00 | +324.0% | (49.60) | Turned profit |
| Net profit for the period | 320.40 | 75.00 | +327.2% | (50.50) | Turned profit |
| EPS, basic (₹) | 17.55 | 4.11 | +327.0% | (2.77) | Turned profit |
| Net margin (%) | 36.2 | 18.3 | -8.5 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 805.70 | 393.80 | +104.6% | 514.10 | +56.7% |
| Other income | 33.20 | 12.30 | +169.9% | 10.40 | +219.2% |
| Total income | 838.90 | 406.10 | +106.6% | 524.50 | +59.9% |
| Profit before tax | 373.00 | 91.00 | +309.9% | (67.10) | Turned profit |
| Net profit for the period | 308.00 | 75.20 | +309.6% | (61.30) | Turned profit |
| EPS, basic (₹) | 16.87 | 4.12 | +309.5% | (3.36) | Turned profit |
| Net margin (%) | 38.2 | 19.1 | -11.9 |
Consolidated
- Filed with BSE
- 10 Aug 2022, 13:15 IST
- Board meeting
- 09 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Aug 2022, 13:15 IST
- Board meeting
- 09 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE